Ysg final ppt 27
-
Upload
anjana-toley -
Category
Health & Medicine
-
view
296 -
download
3
Transcript of Ysg final ppt 27
![Page 1: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/1.jpg)
Anti-Hypertensive Drugs in Pregnancy
Present Scenario
![Page 2: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/2.jpg)
PRE TEXT…..Hypertension complicates
almost 10% of pregnancies.
Progression from mild to severe forms of hypertension during pregnancy is unpredictable and can be rapid.
The use of antihypertensive drugs in pregnancy is
controversial.
![Page 3: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/3.jpg)
Further, treatment of PIH often involves adjustment between
competing concerns for maternal health, gestational age of the infant and fetal
exposure to antihypertensive drugs.
![Page 4: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/4.jpg)
During pregnancy, the priority regarding hypertension is in
making the correct diagnosis, with the emphasis on distinguishing preexisting
(chronic) from pregnancy induced (gestational hypertension and the
syndrome of preeclampsia).
American Heart Assoc. Guidelines 2008
![Page 5: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/5.jpg)
Role of Antihypertensive in Pregnancy
Antihypertensive agents are mainly used to prevent and treat severe
hypertension; to prolong pregnancy for as long as safely
possible, thereby maximizing the gestational age of the infant; and to
minimize fetal exposure to medications that may have adverse
effects.
American Heart Assoc. Guidelines 2008
![Page 6: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/6.jpg)
Some Basic Considerations...
![Page 7: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/7.jpg)
Hypertension in pregnancy is Sustained diastolic BP (DBP) ≥90mm Hg; (most accepted)
Systolic BP ≥140mm Hg (less commonly accepted)
Relative rise in DBP > 15 mm of Hg (Least accepted)
Definition
![Page 8: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/8.jpg)
In general, mild to moderate hypertension in pregnancy reflects a
DBP between 90 and 109mm Hg;
severe hypertension is usually defined as SBP ≥170mm Hg and/or
DBP ≥110mm Hg.
![Page 9: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/9.jpg)
Chronic hypertension diagnosed before pregnancy or within the first 20 weeks' gestation,
Gestational hypertension diagnosed after 20 weeks' not associated with proteinuria
Pre-eclampsia diagnosed after 20 weeks' gestation associated with proteinuria
![Page 10: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/10.jpg)
Classification of Hypertensive disorders in pregnancy
Chronic hypertension Gestational hypertension Develops in 2nd half of
pregnancy Without significant proteinuria BP normalizes by 6 weeks post
partum. Risk of developing preeclampsia
is 15-25%.Pre-eclampsia / Eclampsia
![Page 11: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/11.jpg)
Pre Eclampsia-Eclampsia
• Preeclampsia-eclampsia is a syndrome that manifests clinically as new-onset hypertension in later pregnancy
(any time after 20 weeks, but usually closer to term.With associated• Proteinuria: 1 on dipstick or (300 mg /24 hr Urine)
Occurs in 5% to 8% all pregnancies and is thought to be a consequence ofabnormalities in the maternal vessels
supplying the placenta
![Page 12: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/12.jpg)
Preeclampsia/eclampsia definitions
Preeclampsia: Hypertension >140/90 with proteinuria of at least 0.3g/24hSevere preeclampsia: Preeclampsia with hypertension >160/110 or proteinuria >5g/24h or multiorgan involvementEclampsia: Convulsions in any woman who has, or then presents with, hypertension in pregnancy of any cause
![Page 13: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/13.jpg)
Symptoms other than hypertension and proteinuria in severe preeclampsia
Oliguria (<400 ml/24h)Cerebral signs (headache, blurred vision, altered consciousness)Pulmonary edema, cyanosisEpigastric or right upper quadrant painImpaired liver functionHepatic ruptureTrombocytopeniaHELLP syndrome
![Page 14: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/14.jpg)
CONTROVERSIES ARE….At what level of BP treatment should be
initiated?What is target BP for patient undergoing
treatment?
No evidence to suggest that treatment of gestational or chronic hypertension
prevents development of Pre Eclampsia
Hypertension in Pregnancy:When to treat?
![Page 15: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/15.jpg)
When to treatControversy in mild to moderate
hypertensionB’COZ
Most Anti-hypertensives are in
Category C of FDA safety list.
which states that human studies are lacking, animal studies are either
positive for fetal risk or are lacking.
![Page 16: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/16.jpg)
When to treat…
There is consensus that
severe hypertension in pregnancy,
defined as >160/110 mm Hg, requires treatment, because these women are at an increased risk of intracerebral hemorrhage, and that
treatment decreases the risk of maternal death.
T Podymow, August P. Update on the Use of Antihypertensive Drugs in Pregnancy .Hypertension 2008; 51: 960-969.
![Page 17: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/17.jpg)
When to treat…
There is consensus that
severe hypertension in pregnancy,
defined as >160/110 mm Hg, requires treatment, because these women are at an increased risk of intracerebral hemorrhage, and that
treatment decreases the risk of maternal death.
T Podymow, August P. Update on the Use of Antihypertensive Drugs in Pregnancy .Hypertension 2008; 51: 960-969.
![Page 18: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/18.jpg)
Choice of drugs
The choice of antihypertensive drugs in pregnancy is often limited
due to fetal safety concerns.
![Page 19: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/19.jpg)
Factors affecting choice of anti-hypertensive Drugs
Efficacy Familiarity and experience with the drug Knowledge of doses and interactions with the drug Fetal and maternal adverse effects Effect on utero-placental blood flow Onset of action Duration of action Ease of administration
![Page 20: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/20.jpg)
Drugs administered during gestational days
0 to 17 (during fertilisation and implantation) or days 18 to 55 (when organogenesis takes place) can critically interrupt fetal
structural development.
After day 55, the developing fetus is more resistant to drugs although noxious agents can cause fetal deformation by decreasing
cell size and number.
![Page 21: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/21.jpg)
General Principles for Anti Hypertensive drugs in Pregnancy
When possible, drugs should be avoided in the first trimester
Monotherapy with older and familiar antihypertensives known to have minimal or no maternal or fetal adverse effects is preferred
Episodic treatment should be avoided All antihypertensive drugs affect the mother and the
fetus.
![Page 22: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/22.jpg)
By What To Treat
• Sympatholytics:• Adrenergic receptor Blocker• Vasodilators• Ca Channel blockers• ACE Inhibitors• Angiotensin receptor blockers
![Page 23: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/23.jpg)
MANAGEMENTOf
MILD TO MODERATE HYPERTENSION
BP <160-170 Systolic < 100-110 Diastolic
![Page 24: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/24.jpg)
There is no clear consensus on the management of mild to moderate hypertension
Methyldopa, LabetalolNifedipine
Are acceptable oral antihypertensive agents for this scenario.
![Page 25: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/25.jpg)
Patients with mild Hypertension who may be candidate for Therapy
![Page 26: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/26.jpg)
History of severe HTN in Previous pregnancy
History of abruptio Placenta
History of still birth or unexplained neonatal death
Marked obesity
Older than 35 years
Hypertension for more than !5 years.
![Page 27: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/27.jpg)
Classes Of Drugs Useful in Treatment
DIURETICS
Furosemide
Thiazides
DRUGS that Decrease Cardiac output
Beta Blockers
Propanolol
VasopdilatorsVasopdilators
LabetalolLabetalol
FenoldopamFenoldopam
NicardipineNicardipine
NifidepineNifidepine
PrazosinPrazosin
HydralazineHydralazine
CENTRALLY CENTRALLY ACTING ACTING DRUGSDRUGS
Methyl DopaMethyl Dopa
![Page 28: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/28.jpg)
Methyldopa
![Page 29: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/29.jpg)
METHYL DOPA
0.5 to 3.0 g/d in 2 divided doses
Safety after first trimester well documented, including 7 years follow-up of offsprings
![Page 30: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/30.jpg)
Drug of first choice
for control of mild to moderate'
hypertension in Pregnancy
Most commonly Prescribed
Best documented safety record
Maternal and
Fetal safety record,
(4.5 to 7.5 year)
Follow up data.
Does not alter maternal
Cardiac output
Uterine blood flow and
Renal blood flow.
![Page 31: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/31.jpg)
Alpha methyl Dopa
• When to start BP > 110 mm of Hg diastolicInitial Dose: 250 mg 3-4 times /day Maximum dose 2gm/day BP not controlled : add other
drug
![Page 32: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/32.jpg)
Alpha Methyl Dopa
• Side Effects: Postural Hypertension(dose reduction) Depression Headache Fatigue Depression Drowsiness Salt And water retention----Rebound Htn ( add diuretics) Abnormal LFT
![Page 33: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/33.jpg)
2nd Line Drugs
![Page 34: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/34.jpg)
Calcium channel Blockers
Useful In late pregnancyUseful In late pregnancy,, Good control of maternal BP
Including those with pre-eclampsia,
No adverse fetal or perinatal effects.
Little data regarding their safety in early pregnancy
Nifidepine is Most Commonly used drug
![Page 35: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/35.jpg)
Nifedipine/Calcium channel Blockers
30 to 120 mg/d of a slow-release preparation
..May inhibit labor
..Has synergistic action with magnesium
sulfate in BP lowering;
..Little experience with other calcium entry blockers
![Page 36: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/36.jpg)
Labetalol Combined alpha & beta adrenergic blockerCombined alpha & beta adrenergic blocker Is a peripheral vascular dilator As effective as Methyldopa in pre-eclamptic and
non-proteinuric hypertension in pregnancy. PROBABLY as safe as methyl dopa Long term safety not established 2nd Line drug for this reason
![Page 37: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/37.jpg)
Labetlol
• Non selective B blocker• Mechanism of action Blocks –alpha 1 , Beta 1 & 2 receptors Decreases peripheral Vascular
resistance No effect on utero-placental blood flow Cardiac output not affected•
![Page 38: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/38.jpg)
Labetalol
200 to 1200 mg/d in 2 to 3 divided doses
May be associated with fetal growth restriction
![Page 39: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/39.jpg)
Labetalol • Side Effects:Side Effects: Tremors Headache Asthma CCF Fetal hypoglycemia• Contrindications:Contrindications: Hepatic disorders Asthma CCF
![Page 40: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/40.jpg)
Choice Between
Alpha Methyl Dopa
Labetalol
Nifedipine
![Page 41: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/41.jpg)
Labetalol was more effective than methyldopa and nifedipine in controlling blood pressure in
patients with pregnancy-induced hypertension while methyldopa
and nifedipine are equally effective in controlling blood
pressure.
IJBCP International Journal of Basic & Clinical Pharmacology.
![Page 42: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/42.jpg)
Severe Hypertension
There is consensus that severe hypertension in pregnancy, defined as >160/110 mm Hg, requires treatment, because these women are at an
increased risk of intracerebral hemorrhage, and that treatment decreases the risk of maternal
death.
![Page 43: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/43.jpg)
Which Drug Is to be used ?
Do We Have any Choice Preferrence ?
![Page 44: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/44.jpg)
A recent meta-analysis of 24 trials (2949 women) in which different
antihypertensive drugs were compared for the treatment of severe hypertension in pregnancy concluded that there is insufficient data to favor one agent over another.
![Page 45: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/45.jpg)
Management of severe hypertension
Hydralazine (I.V.) Labetalol (I.V) Sublingual Nifidepine I.V.Isradepine Diazoxide Sodium Nitroprusside
![Page 46: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/46.jpg)
Drugs useful in parenteral route
1.Labetalol2.Hydralazine3.Nifedepine4.Diazoxide5.Nitroprusside
![Page 47: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/47.jpg)
Who require par-entral treatmentWho require par-entral treatmentHypertensive encephalopathy, Hemorrhage, or Eclampsia
Target is :To lower
Mean Arterial Pressure by 25% over minutes to hours
and then to further lower BP to 160/100 mm Hg over subsequent hours
Caution: Avoid Hypotension
![Page 48: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/48.jpg)
Those with hypertensive encephalopathy, hemorrhage, or eclampsia require treatment with parenteral agents to lower mean arterial pressure by 25%
over minutes to hours and then to further lower BP to 160/100 mm Hg
over subsequent hours.
In treating severe hypertension, it is important to avoid hypotension,
because the degree to which placental blood flow is
autoregulated is not established, and aggressive lowering may
cause fetal distress.
![Page 49: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/49.jpg)
Hydarlazine
Drug of first choice for severe HTN
ADVANTAGES ARE
No adverse effects on fetal circulation, Long experience with the drug in this
clinical setting, Convenient administration
![Page 50: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/50.jpg)
Hydarlazine
Laimed to be Drug of first choice for severe HTN
ADVANTAGES ARE
No adverse effects on fetal circulation, Long experience with the drug in this
clinical setting, Convenient administration
![Page 51: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/51.jpg)
Disadvantages of Hydralazine
Adverse effects
Mimicking HEELLP Syndrome Maternal hypotension Fetal heart rate deceleration Possible increased tendency to cause
serious ventricular arrhythmias compared with labetalol
May cause neonatal thrombocytopenia
![Page 52: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/52.jpg)
Hydralazine
50 to 300 mg/d in 2 to 4 divided doses
Few controlled trials,
long experience with few adverse
events documented;
useful in combination with sympatholytic agent;
![Page 53: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/53.jpg)
Labetalol
Experience with labetalol in the acute treatment of severe hypertension in pregnancy is less well documented.
Studies suggest that parenteral use of labetalol is at least effective and safe as hydralazine.
Fetal distress and neonatal bradycardia have been reported.
![Page 54: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/54.jpg)
Nifedipine
Oral/sublingual has been reported to be as safe and effective as
intravenous hydralazine for the acute treatment of severe
hypertension in pregnancy.
![Page 55: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/55.jpg)
Nifedipine With MgSO4
Has been associated with maternal hypotension (and fetal distress).
Neuromuscular Blockade has been reported.
While the drugs should be used together with caution, their combined use is common practice in some delivery suites.
Short-acting nifedipine capsules have been withdrawn in some countries
![Page 56: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/56.jpg)
Isradipine....a new weapon
Intravenous Isradipine has also been shown to be effective in severe pregnancy-associated
hypertension, although it has not been extensively studied in this
clinical setting
![Page 57: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/57.jpg)
Diazoxide
Diazoxide is a potent antihypertensive
Can interfere with glucose metabolism.
Should be reserved for patients with severe hypertension unresponsive to hydralazine, nifedipine or labetalol.
![Page 58: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/58.jpg)
Special Consideratrions
Eclampsia
Prevention of Pre- Eclampsia
Ecosprin, Antioxidants, Calcium Supp
Pre Conceptional Counselling
![Page 59: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/59.jpg)
Impending eclampsia
Severe preeclampsia with signs of cerebral affection like visual disturbancies, headache, increased reflexes, and clonus
BJA 1996: 76: 133-148
![Page 60: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/60.jpg)
The treatment of choice for eclampsia and prophylaxis against recurrent convulsions is magnesium sulphate (Lancet 1995: 345: 1456-1463)
Magnesium sulphate is also the drug of choice for seizure prophylaxis in patients with preeclampsia
(Lancet 2002: 359: 1877-1890)
![Page 61: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/61.jpg)
Magnesium Sulphate
Drug of Choice for T/t
Of
Eclampsia
Has Narrow Range of
Therapeutic
Safety
Areflexia, particularly loss of the
patellar deep tendon reflex,
has been observed at 8 to 10 mEq/L
Respiratory paralysis
seen at >13 mEq/L
Serum Concentrari
ons between
3.5-7 meq/l are
therapeutic
Normal serum concentrations of Mg2+ are 1.5 to 2.5 mEq/L (1.8 to 3.0 mg/dL),
![Page 62: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/62.jpg)
”Delivery of the fetus and placenta is the definitive management of severe preeclampsia. Once severe disease has been established and is progressing, delivery of the fetus and placenta must be accomplished to limit maternal risk.”
Int Care Med 1997: 23: 248-255
![Page 63: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/63.jpg)
Prevention Of Pre-eclampsia
![Page 64: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/64.jpg)
ASPIRIN MAY PREVENT
Low-dose acetylsalicylic acid (aspirin, 75 mg) is recommended for theprevention of pre-eclampsia in women at
high risk of developing theCondition
WHO Guidelibes 2010
![Page 65: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/65.jpg)
Calcium Supplementation
In areas where dietary calcium intake is low, calcium supplementation
during pregnancy (at doses of 1.5–2.0 g elemental calcium/day) is
recommended for the prevention of pre-eclampsia in all women, but
especially those at high risk of developing pre-eclampsia
![Page 66: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/66.jpg)
Rest May Not help in preventionweak Evidence
Advice to rest at home is not recommended as an intervention for
the primary prevention of pre-eclampsia
and hypertensive disorders of pregnancy in womenconsidered to
be at risk of developing those condition
![Page 67: Ysg final ppt 27](https://reader036.fdocuments.net/reader036/viewer/2022062418/554b04c8b4c905c12d8b511e/html5/thumbnails/67.jpg)
Pre Conceptional Counselling
Indicated in
Patients who are chronic Hypertensive, Planning to
have pregnancy.
ACE Inhibitors may be replaced with other drugs as they are fetotoxic